Sparks commentary

Healthcare

Sparks

Tissue Regenix (LSE: TRX) announces H124 results
Published by Arron Aatkar, PhD

Tissue Regenix’s H124 results reflect sustained progress across its multiple areas of business, with revenues increasing by 16% to US$16.4m (H123: US$14.1m). This was largely driven by the robust performance of its key technology platforms, BioRinse (sales up by 12% to US$10.5m; H123: US$9.4m) and dCELL (sales up by 34% to US$4.2m; H123: US$3.1m). Gross profit also increased to 53% (H123: 49%) due to greater processing efficiencies and a favourable product mix. The company ended the period with a cash position of US$3.5m, which should see it through current business plans, including the Phase 2 capacity expansion of its San Antonio facility, expected to complete in 2025. Collectively, these results mark Tissue Regenix’s eighth consecutive period of growth and the seventh consecutive period of double-digit, half-on-half growth.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.